Moreover, to examine the impact of CAFs and TGF-β1 on RAP2 expression, neutralizing anti-TGF-β1 antibody or TGF-β1 cascade inhibitor SB431542 will be utilized to antagonize the TGF-β1 signal to block cell-cell interaction for uncovering whether the TGF-β1-c-Myc-RAP2 axis could mediate the interaction between CAFs and pancreatic cancer cells. This evidence concerns the gene RAP2A and pancreatic neoplasm.